Is Revolution Medicines Inc (RVMD) a Stock to Watch After Losing -3.22% This Week?

Revolution Medicines Inc (RVMD) stock is lower by 3.22% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Revolution Medicines Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock is trading at $31.86 as of 12:41 PM on Monday, Mar 18, a rise of $0.03, or 0.09% from the previous closing price of $31.83. Volume today is low. So far 621,030 shares have traded compared to average volume of 1,634,446 shares. The stock has traded between $31.24 and $32.17 so far today. To see InvestorsObserver's Sentiment Score for Revolution Medicines Inc click here.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.